"Upon commercialization, we believe the IRIS system can meet the needs of a currently underserved patient population that requires physiological, less invasive options to treat functional mitral regurgitation in patients with progressive heart failure," said Professor Ian Meredith, executive vice president and global chief medical officer at Boston Scientific. "This device is designed to be highly customizable to a specific patient's mitral anatomy and disease state, and is repositionable and retrievable to promote a high-quality outcome."

The agreement is predicted to close in the first quarter of 2019, with the transaction expected to be dilutive to earnings per share (EPS) for each of the next several years. International trade-offs, though, are anticipated to absorb all dilutive impact, ensuring no net adjusted EPS impact. On a GAAP basis, the deal is expected to be more dilutive for each of the next several years, due to amortization expense and acquisition-related net charges. The agreement is subject to customary closing conditions.


The IRIS Transcatheter Annuloplasty Ring System is an investigational device and is not available for sale.

Back to HCB News

Cardiology Homepage